ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
70.13
+0.11 (0.16%)
At close: Aug 8, 2025, 4:00 PM
69.95
-0.18 (-0.26%)
After-hours: Aug 8, 2025, 7:54 PM EDT
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 69 employees as of December 31, 2024. The number of employees increased by 8 or 13.11% compared to the previous year.
Employees
69
Change (1Y)
8
Growth (1Y)
13.11%
Revenue / Employee
$165,855
Profits / Employee
-$2,909,594
Market Cap
5.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69 | 8 | 13.11% |
Dec 31, 2023 | 61 | 37 | 154.17% |
Dec 31, 2022 | 24 | 0 | - |
Dec 31, 2021 | 24 | -3 | -11.11% |
Dec 31, 2020 | 27 | 1 | 3.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ABVX News
- 12 days ago - Abivax Announces Closing of $747.5 Million Public Offering - GlobeNewsWire
- 15 days ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) - GlobeNewsWire
- 16 days ago - Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst - Seeking Alpha
- 16 days ago - Abivax announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire
- 16 days ago - Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares - GlobeNewsWire
- 16 days ago - Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewsWire
- 17 days ago - Abivax Announces Launch of Public Offering - GlobeNewsWire
- 17 days ago - Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity - Seeking Alpha